246 related articles for article (PubMed ID: 18160670)
21. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms.
Grockowiak E; Korn C; Rak J; Lysenko V; Hallou A; Panvini FM; Williams M; Fielding C; Fang Z; Khatib-Massalha E; García-García A; Li J; Khorshed RA; González-Antón S; Baxter EJ; Kusumbe A; Wilkins BS; Green A; Simons BD; Harrison CN; Green AR; Lo Celso C; Theocharides APA; Méndez-Ferrer S
Nat Cancer; 2023 Aug; 4(8):1193-1209. PubMed ID: 37550517
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms.
Bekendam RH; Ravid K
Front Cell Dev Biol; 2023; 11():1207395. PubMed ID: 37457287
[TBL] [Abstract][Full Text] [Related]
23. Exploration and identification of anoikis-related genes in polycythemia vera.
Aini W; Xie L; Hu W; Tang Y; Peng H; Zhang G; Deng T
Front Genet; 2023; 14():1139351. PubMed ID: 36873934
[No Abstract] [Full Text] [Related]
24. Factors associated with clonal hematopoiesis and interaction with marrow environment.
Nannya Y
J Bone Miner Metab; 2023 May; 41(3):380-387. PubMed ID: 36346484
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.
Rai S; Grockowiak E; Hansen N; Luque Paz D; Stoll CB; Hao-Shen H; Mild-Schneider G; Dirnhofer S; Farady CJ; Méndez-Ferrer S; Skoda RC
Nat Commun; 2022 Sep; 13(1):5346. PubMed ID: 36100613
[TBL] [Abstract][Full Text] [Related]
26. Megakaryocytes as the Regulator of the Hematopoietic Vascular Niche.
Zhan H; Kaushansky K
Front Oncol; 2022; 12():912060. PubMed ID: 35814384
[TBL] [Abstract][Full Text] [Related]
27. PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in
Wang JC; Sun L
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628647
[TBL] [Abstract][Full Text] [Related]
28. JAK2V617F Mutant Megakaryocytes Contribute to Hematopoietic Aging in a Murine Model of Myeloproliferative Neoplasm.
Lee S; Wong H; Castiglione M; Murphy M; Kaushansky K; Zhan H
Stem Cells; 2022 Apr; 40(4):359-370. PubMed ID: 35260895
[TBL] [Abstract][Full Text] [Related]
29. Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.
Gou P; Zhang W; Giraudier S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162937
[TBL] [Abstract][Full Text] [Related]
30. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract][Full Text] [Related]
31. Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.
Easwar A; Siddon AJ
Life (Basel); 2021 Oct; 11(11):. PubMed ID: 34833034
[TBL] [Abstract][Full Text] [Related]
32. A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm.
Zhang H; Yeware A; Lee S; Zhan H
Front Oncol; 2021; 11():753465. PubMed ID: 34765558
[TBL] [Abstract][Full Text] [Related]
33. CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of
Chen M; Zhang C; Hu Z; Li Z; Li M; Wu L; Zhou M; Liang D
Biosensors (Basel); 2021 Jul; 11(8):. PubMed ID: 34436049
[TBL] [Abstract][Full Text] [Related]
34. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
Varricchio L; Iancu-Rubin C; Upadhyaya B; Zingariello M; Martelli F; Verachi P; Clementelli C; Denis JF; Rahman AH; Tremblay G; Mascarenhas J; Mesa RA; O'Connor-McCourt M; Migliaccio AR; Hoffman R
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34383713
[TBL] [Abstract][Full Text] [Related]
35. Cell competition between wild-type and JAK2V617F mutant cells in a murine model of a myeloproliferative neoplasm.
Castiglione M; Zhang H; Kaushansky K; Zhan H
Exp Hematol; 2021 Aug; 100():52-62. PubMed ID: 34153382
[TBL] [Abstract][Full Text] [Related]
36. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.
Mazzeo C; Quan M; Wong H; Castiglione M; Kaushansky K; Zhan H
Blood Cells Mol Dis; 2021 Sep; 90():102585. PubMed ID: 34139651
[TBL] [Abstract][Full Text] [Related]
37. Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms.
Secardin L; Gomez Limia C; da Silva-Benedito S; Lordier L; El-Khoury M; Marty C; Ianotto JC; Raslova H; Constantinescu SN; Bonamino MH; Vainchenker W; Monte-Mor B; Di Stefano A; Plo I
Hemasphere; 2021 Jul; 5(7):e593. PubMed ID: 34131633
[TBL] [Abstract][Full Text] [Related]
38. Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.
Stuckey R; Gómez-Casares MT
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068690
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms.
Tong J; Sun T; Ma S; Zhao Y; Ju M; Gao Y; Zhu P; Tan P; Fu R; Zhang A; Wang D; Wang D; Xiao Z; Zhou J; Yang R; Loughran SJ; Li J; Green AR; Bresnick EH; Wang D; Cheng T; Zhang L; Shi L
Cell Stem Cell; 2021 Apr; 28(4):780. PubMed ID: 33798424
[TBL] [Abstract][Full Text] [Related]
40. The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.
Spivak JL; Moliterno AR
Front Oncol; 2021; 11():641613. PubMed ID: 33777803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
